SCHEMBL2333763

SCHEMBL2333763

CCCCc1cc2cc(Br)ccc2o1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.47
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
CYP2A6 P11509 1/20 0.44
TLR8 Q9NR97 1/20 0.43
USP2 O75604 1/20 0.43
PIM1 P11309 1/20 0.42
MAOA P21397 1/20 0.42
ALOX15 P16050 1/20 0.41
F2 P00734 1/20 0.41
F10 P00742 1/20 0.41
MAPT P10636 1/20 0.40
MMP2 P08253 1/20 0.40
MMP9 P14780 1/20 0.40
ADAM17 P78536 1/20 0.40
GRIN1 Q05586 1/20 0.40
GRIN2A Q12879 1/20 0.40
GRIN2B Q13224 1/20 0.40
GRIN2C Q14957 1/20 0.40
GPR35 Q9HC97 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7469284 0.95 ALOX15 (0.47) CYP19A1NPC1RAB9ACYP2A6TLR8
SCHEMBL7463986 0.94 MAPT (0.48) CYP19A1NPC1RAB9ACYP2A6TLR8
SCHEMBL6301307 0.90 CYP19A1 (0.49) CYP19A1NPC1RAB9ACYP2A6TLR8
SCHEMBL2785591 0.83 CYP19A1 (0.47) CYP19A1NPC1RAB9ACYP2A6USP2
SCHEMBL30317998 0.82 CYP19A1 (0.51) CYP19A1NPC1RAB9ACYP2A6USP2
SCHEMBL6300586 0.82 CYP19A1 (0.51) CYP19A1NPC1RAB9ACYP2A6USP2
SCHEMBL12370192 0.81 TLR8 (0.44) TLR8MAOAALOX15F2F10
SCHEMBL2330441 0.80 ALOX15 (0.58) TLR8MAOAALOX15F2F10
SCHEMBL8950010 0.80 ALDH1A1 (0.50) CYP19A1NPC1RAB9ACYP2A6USP2
SCHEMBL284155 0.80 TLR8 (0.50) NPC1TLR8MAOAALOX15F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115521277-A Method for preparing benzofuran compound 山东新时代药业有限公司 2022-12-27 CN disclosed
EP-3039016-B1 PROCESS FOR PREPARING DRONEDARONE AND SALTS THEREOF GILEAD SCIENCES INC (US) 2017-08-02 EP disclosed
US-9334254-B2 Process for preparing sulfonamidobenzofuran derivatives SANOFI (FR) 2016-05-10 US disclosed
US-9242953-B2 Process for preparing dronedarone and salts thereof GILEAD SCIENCES, INC. (US) 2016-01-26 US disclosed
US-9242953-B2 Process for preparing dronedarone and salts thereof GILEAD SCIENCES, INC. (US) 2016-01-26 US disclosed
WO-2015031352-A1 PROCESS FOR PREPARING DRONEDARONE AND SALTS THEREOF GILEAD SCIENCES, INC. (US) 2015-03-05 WO disclosed
US-20150065734-A1 PROCESS FOR PREPARING DRONEDARONE AND SALTS THEREOF GILEAD SCIENCES, INC. (US) 2015-03-05 US disclosed
US-20150065734-A1 PROCESS FOR PREPARING DRONEDARONE AND SALTS THEREOF GILEAD SCIENCES, INC. (US) 2015-03-05 US disclosed
US-8871956-B2 Method for preparing 3-keto-benzofurane derivatives SANOFI (FR) 2014-10-28 US disclosed
US-20130165673-A1 METHOD FOR PREPARING 3-KETO-BENZOFURANE DERIVATIVES SANOFI (FR) 2013-06-27 US disclosed
US-20130046103-A1 PREPARATION OF BENZOFURANS AND USE THEREOF AS SYNTHETIC INTERMEDIATES MAPI PHARMA LIMITED (IL) 2013-02-21 US disclosed
US-20130046103-A1 PREPARATION OF BENZOFURANS AND USE THEREOF AS SYNTHETIC INTERMEDIATES MAPI PHARMA LIMITED (IL) 2013-02-21 US disclosed
EP-2552899-A1 PROCESS FOR PREPARING SULFONAMIDO-BENZOFURAN DERIVATIVES SANOFI (FR) 2013-02-06 EP disclosed
EP-2552898-A1 METHOD FOR PREPARING 3-KETO-BENZOFURANE DERIVATIVES SANOFI (FR) 2013-02-06 EP disclosed
US-20130023678-A1 PROCESS FOR PREPARING SULFONAMIDOBENZOFURAN DERIVATIVES SANOFI (FR) 2013-01-24 US disclosed
EP-2533636-A1 PREPARATION OF BENZOFURANS AND USE THEREOF AS SYNTHETIC INTERMEDIATES Mapi Pharma Limited (IL) 2012-12-19 EP disclosed
CN-102753018-A Preparation of benzofurans and their use as synthetic intermediates MAPI PHARMA HOLDINGS CYPRUS LTD 2012-10-24 CN disclosed
WO-2011131881-A1 METHOD FOR PREPARING 3-KETO-BENZOFURANE DERIVATIVES SANOFI-AVENTIS (FR) 2011-10-27 WO disclosed
WO-2011124827-A1 PROCESS FOR PREPARING SULFONAMIDO-BENZOFURAN DERIVATIVES SANOFI-AVENTIS (FR) 2011-10-13 WO disclosed
WO-2011099010-A1 PREPARATION OF BENZOFURANS AND USE THEREOF AS SYNTHETIC INTERMEDIATES MAPI PHARMA HOLDINGS (CYPRUS) LIMITED (CY) 2011-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165673-A1 METHOD FOR PREPARING 3-KETO-BENZOFURANE DERIVATIVES CYP2F1, CBR3, STS CYP19A1 520/4885NPC1 3779/4885RAB9A 2035/4885
US-20150065734-A1 PROCESS FOR PREPARING DRONEDARONE AND SALTS THEREOF CYP2D6, CYP3A43, CYP3A4 CYP19A1 631/4885NPC1 303/4885RAB9A 144/4885
US-20130046103-A1 PREPARATION OF BENZOFURANS AND USE THEREOF AS SYNTHETIC INTERMEDIATES CYP2F1, CYP4F3, CYP2D6 CYP19A1 319/4885NPC1 1648/4885RAB9A 1482/4885
US-20130023678-A1 PROCESS FOR PREPARING SULFONAMIDOBENZOFURAN DERIVATIVES CYP2F1, STS, SULT1E1 CYP19A1 878/4885NPC1 4109/4885RAB9A 2601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.